Abstract
To fully define HLA-A11- restricted HIV-1- specific cytotoxic T-lymphocyte epitopes in China, a method combining the enzyme-linked immunospot (ELISPOT) assay with intracellular gamma interferon staining (ICS) of peripheral blood mononuclear cells (PBMC) was used to map the optimal epitopes targeted by ELISPOT and then to define the HLA restriction of epitopes by ICS. A novel HLA-A11-restricted CTL epitope and five other published HLA-A11-restricted epitopes previously identified by reverse immunogenetics or other methods were defined. The approach of integrating ELISPOT with ICS is both convenient and useful for the characterization of CTL responses to HIV-1 infection; this method is practical for defining novel epitopes and facilitates in developing new strategies for future vaccine design in China and other Asian countries.
Keywords: HIV, cytotoxic T-lymphocyte, epitopes, enzyme-linked immunospot (ELISPOT) assay, intracellular gamma interferon staining (ICS)
Current HIV Research
Title: Identification of HLA-A11-Restricted HIV-1-Specific Cytotoxic Tlymphocyte Epitopes in China
Volume: 5 Issue: 1
Author(s): Shaoyang Wang, Yongtao Sun, Song Zhai, Yan Zhuang, Shuguang Zhao, Whenzhen Kang, Xinhong Li, Dedong Huang, Xu G. Yu, Bruce D. Walker and Marcus A. Altfeld
Affiliation:
Keywords: HIV, cytotoxic T-lymphocyte, epitopes, enzyme-linked immunospot (ELISPOT) assay, intracellular gamma interferon staining (ICS)
Abstract: To fully define HLA-A11- restricted HIV-1- specific cytotoxic T-lymphocyte epitopes in China, a method combining the enzyme-linked immunospot (ELISPOT) assay with intracellular gamma interferon staining (ICS) of peripheral blood mononuclear cells (PBMC) was used to map the optimal epitopes targeted by ELISPOT and then to define the HLA restriction of epitopes by ICS. A novel HLA-A11-restricted CTL epitope and five other published HLA-A11-restricted epitopes previously identified by reverse immunogenetics or other methods were defined. The approach of integrating ELISPOT with ICS is both convenient and useful for the characterization of CTL responses to HIV-1 infection; this method is practical for defining novel epitopes and facilitates in developing new strategies for future vaccine design in China and other Asian countries.
Export Options
About this article
Cite this article as:
Wang Shaoyang, Sun Yongtao, Zhai Song, Zhuang Yan, Zhao Shuguang, Kang Whenzhen, Li Xinhong, Huang Dedong, Yu G. Xu, Walker D. Bruce and Altfeld A. Marcus, Identification of HLA-A11-Restricted HIV-1-Specific Cytotoxic Tlymphocyte Epitopes in China, Current HIV Research 2007; 5 (1) . https://dx.doi.org/10.2174/157016207779316404
DOI https://dx.doi.org/10.2174/157016207779316404 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sphingolipid Metabolism and Leukemia: A Potential for Novel Therapeutic Approaches
Anti-Cancer Agents in Medicinal Chemistry Antimicrobial Peptides: Mediators of Innate Immunity as Templates for the Development of Novel Anti-Infective and Immune Therapeutics
Current Pharmaceutical Design Peroxisome Proliferator Activated Receptor-Gamma Ligands as Potent Antineoplastic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Production of Orally Applicable New Drug or Drug Combinations from Natural Origin Capsaicinoids for Human Medical Therapy
Current Pharmaceutical Design Opioids in Neuropathic Pain
Current Pharmaceutical Design Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Current Cancer Drug Targets CXCR4-CXCL12-Dependent Inflammatory Network and Endothelial Progenitors
Current Medicinal Chemistry Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Inflammatory Cytokines and Cardiovascular Disease
Current Drug Targets - Inflammation & Allergy From Pharmacotherapy to Pathophysiology: Emerging Mechanisms of Apolipoprotein D in Psychiatric Disorders
Current Molecular Medicine Natural Products Mediated Regulation of Oxidative Stress and DNA Damage in Ultraviolet Exposed Skin Cells
Current Pharmaceutical Biotechnology Allergic Contact Dermatitis: Novel Mechanisms and Therapeutic Perspectives
Current Drug Metabolism Role of Hsp70 in Cancer Growth and Survival
Protein & Peptide Letters Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities
Current Pharmaceutical Biotechnology An Overview of Immunotherapy for Allergic Disease: New Developments and Future Strategies
Medicinal Chemistry Reviews - Online (Discontinued) MicroRNA-155 Regulates Inflammatory Response in Ischemic Cerebral Tissues through Autophagy
Current Neurovascular Research Pharmacognostical Overview of “Gunma Kuligai” – a Traditional Siddha Preparation for Treating Acid Peptic Disease (APD)
Current Traditional Medicine Progress in the Diagnosis and Treatment of Pulmonary Aspergillosis
Current Respiratory Medicine Reviews Fibroblast Growth Factor-2, Bone Homeostasis and Fracture Repair
Current Pharmaceutical Design Epidural Analgesia in the Post-Anaesthesia Care Unit
Current Drug Targets